Krystal Biotech Subsidiary Announces Positive Results from Phase 1 Study of KB304 for Wrinkle Treatment

Krystal Biotech's subsidiary Jeune Aesthetics reported positive safety and efficacy results for KB304, a treatment for wrinkles on the decollete. The Phase 1 study showed significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, with 81.8% of subjects reporting improved satisfaction with their wrinkles' appearance three months after treatment. The KB304 safety profile was consistent with prior clinical experience.

Title: Jeune Aesthetics Reports Positive Safety and Efficacy Results for KB304 in Phase 1 Study

PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. (NASDAQ: KRYS), has announced positive safety and efficacy results for KB304, a treatment for wrinkles on the décolleté. The results were presented in the Phase 1 study, PEARL-2, which evaluated KB304's ability to deliver collagen and elastin to the skin.

The study, which enrolled 19 subjects and randomized 12 to KB304 and seven to placebo, reported significant improvements in key skin aesthetic attributes such as wrinkles and elasticity. The Global Aesthetic Improvement Scale (GAIS) and the Subject Satisfaction Questionnaire (SSQ) were used to assess the improvements. According to GAIS, 100% of KB304-treated subjects demonstrated at least a one-point improvement in wrinkles and other attributes such as elasticity, crepiness, hydration, and radiance at one, two, and three months following treatment. The SSQ indicated that 81.8% of KB304-treated subjects reported improved satisfaction with their wrinkles' appearance three months after treatment, compared to 14.3% of placebo-treated subjects.

The safety profile of KB304 was consistent with prior clinical experience, with adverse events being mild to moderate and mostly reported after the first dose. No severe or drug-related serious adverse events were reported.

Marc Forth, Chief Executive Officer of Jeune, expressed excitement about the results, stating, "We are very excited to share today’s data update. We are pleased that both the investigator and subjects reported high rates of improvements across a variety of skin attributes when treated with KB304. We believe that KB304 has the potential to revolutionize the treatment of wrinkles and skin quality by directly addressing the underlying biology of aging skin."

Suma Krishnan, President of Research & Development at Krystal Biotech, added, "We are extremely excited by the promising data from the PEARL-2 study. We believe KB304 has the potential to be a first-in-class treatment to deliver collagen and elastin directly to the skin. This study is the first randomized, double-blind, placebo-controlled trial to investigate the potential combinatorial benefits of COL3 and elastin supplementation when produced by the body’s own skin cells."

Jeune Aesthetics and Krystal Biotech will host a conference call and webcast today, Thursday, July 24, 2025, at 4:30 pm ET, to discuss the results of the PEARL-2 study, the KB304 clinical development program, and the strategic vision for Jeune.

References
1. [1] https://ir.krystalbio.com/news-releases/news-release-details/jeune-announces-positive-results-and-significant-aesthetic